IPAS Novel PPARγ Antagonist – the answer for more effective and safer Type II Diabetes treatment
IPAS researchers have been investigating safer drugs against type two diabetes which are effective at increasing insulin sensitivity without causing side effects. The team has successfully used a number of analytical techniques to determine how these new and improved drugs interact with their target in the body. Their work builds on from previous research undertaken by themselves and others around the globe which focusses on a critical aspect on the development of what can often be a debilitating or even life-threatening condition.
PPARγ in Complex with an Antagonist and Inverse Agonist: A Tumble and Trap Mechanism of the Activation Helix
Rebecca L. Frkic, Andrew C. Marshall, Anne-Laure Blayo, Tara L. Pukala, Theodore M. Kamenecka, Patrick R. Griffin, John B. Bruning